Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
At the 12mg dose in TRIUMPH-1: Average weight loss of 28.3% at 80 weeks within the range of bariatric surgery outcomes 45.3% of participants lost 30% or more the threshold associated with bariatric surgery in published literature 65.3% achieved BMI below 30 no longer classifiable as obese by standard criteria Extension data to 104 weeks shows 30.3% average continuing to approach surgical outcomes with longer treatment The comparison is not a simple equivalence
The idea
That doesnt mean the medications are necessarily causing these symptoms, but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically. In the short term, the team hopes their findings will prompt healthcare providers and researchers to pay closer attention to patient discussions online
Four of 8 patients (50%) developed recurrent NASH and 3/8 (37.5%) developed recurrent NASH with fibrosis by a mean of 5.3 years post-transplant
US$ 25.23
US$ 22.83
US$ 20.71
US$ 28.72
